The DOI matches its OpenAlex record.
Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups
Open accessAbstract
Prevalence rates are used to supplement descriptions of disease and are unavailable for all primary brain tumors in the United States. Data from two population-based tumor registries were obtained from the Central Brain Tumor Registry of the United States and used to compute age-specific incidence rates (1985-1994) and survival curves for further use in a statistical model to estimate prevalence rates. Prevalence rates were then used to estimate the number of individuals living with a brain tumor diagnosis in the U.S. population for the year 2000. The overall incidence rate in these regions is 13.8 per 100,000 with 2-, 5-, and 10-year survival rates of 58%, 49%, and 38%, respectively. The prevalence rate for all primary brain tumors is 130.8 per 100,000 with approximately 350,000 individuals estimated to be living with this diagnosis in the United States in 2000. The prevalence rate for malignant tumors, 29.5 per 100,000, is similar to previous reports. The prevalence rate for benign tumors, 97.5 per 100,000, is new. Unlike incidence data, the proportion (and expected number) of existing benign tumors (75%, 267,000) is considerably greater than that for malignant tumors (23%, 81,000), reflecting the better prognosis of benign tumors diagnosed in individuals younger than 60 years old. These data underscore the impact of primary brain tumors in the U.S. health care system and emphasize the need for quality-of-life considerations, particularly for those long-term survivors of benign tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Epidemiology of primary brain tumors: Current concepts and review of the literature
Wrensch, M., Minn, Y., Chew, T., Bondy, M., & Berger, M. S. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.4.278 · Cited by 837
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review
Rogers, L., Barani, I., Chamberlain, M., Kaley, T. J., McDermott, M., Raizer, J., Schiff, D., Weber, D. C., Wen, P. Y., & Vogelbaum, M. A. (2015) · Journal of Neurosurgery · doi:10.3171/2014.7.jns131644 · Cited by 698
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1
Hussain, S. F., Yang, D., Suki, D., Aldape, K., Grimm, E., & Heimberger, A. B. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-008 · Cited by 592
Emerging insights into the molecular and cellular basis of glioblastoma
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 565
Yu, J. S., Liu, G., Ying, H., Yong, W. H., Black, K. L., & Wheeler, C. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3505 · Cited by 537
Fisher, J. L., Schwartzbaum, J. A., Wrensch, M., & Wiemels, J. L. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.002 · Cited by 528
Glioblastoma: From Molecular Pathology to Targeted Treatment
Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130324 · Cited by 518
A highlight on Sonic hedgehog pathway
Carballo, G. B., Honorato, J. R., de Lopes, G. P. F., & Spohr, T. C. L. D. S. E. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0220-7 · Cited by 460
Gurney, J. G., Kadan‐Lottick, N. S., Packer, R. J., Neglia, J. P., Sklar, C. A., Punyko, J. A., Stovall, M., Yasui, Y., Nicholson, H. S., Wolden, S., et al. (2003) · Cancer · doi:10.1002/cncr.11095 · Cited by 369
Porter, K. R., McCarthy, B. J., Freels, S., Kim, Y., & Davis, F. G. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop066 · Cited by 342
Self-citationde Robles, P., Fiest, K. M., Frolkis, A. D., Pringsheim, T., Atta, C., St. Germaine-Smith, C., Day, L., Lam, D., & Jette, N. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou283 · Cited by 338
Caring for the brain tumor patient: Family caregiver burden and unmet needs
Schubart, J. R., Kinzie, M. B., & Farace, E. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-040 · Cited by 329
Incidental findings in magnetic resonance imaging of the brains of healthy young men
Weber, F., & Knopf, H. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.09.008 · Cited by 304
Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients
Wheeler, C. J., Black, K. L., Liu, G., Mazer, M., Zhang, X.-X., Pepkowitz, S., Goldfinger, D., Ng, H., Irvin, D., & Yu, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5973 · Cited by 296
Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination
Wheeler, C. J., Das, A., Liu, G., Yu, J. S., & Black, K. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0497 · Cited by 266
Agarwal, S., Sane, R., Gallardo, J. L., Ohlfest, J. R., & Elmquist, W. F. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167601 · Cited by 255
Virtual magnetic resonance elastography predicts the intraoperative consistency of meningiomas
Aunan-Diop, J. S., Andersen, M. C. S., Friismose, A. I., Halle, B., Pedersen, C. B., Mussmann, B., Grønhøj, M. H., Nielsen, T. H., Jensen, U., & Poulsen, F. R. (2023) · Journal of Neuroradiology · doi:10.1016/j.neurad.2022.10.006 · Cited by 25
Metadata
- Authors
- Davis, F. G., Kupelian, V. A., Freels, S. A., McCarthy, B. J., & Surawicz, T. S.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press
- Published
- 2001-07-01
- Volume
- 3
- Issue
- 3
- Pages
- 152-158
- ISSN
- 1522-8517 (ISSN-L)
- OpenAlex
- W2125149165
- Cited by
- 204
- References
- 0
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.